Matthew Stober Joins the Board of Directors at GeminiBio, Enhancing Biomanufacturing Insights

Matthew Stober Joins the Board of Directors at GeminiBio

In a significant move for the biopharma sector, Gemini Bioproducts, LLC (commonly known as GeminiBio) has welcomed Matthew Stober to its Board of Directors. This announcement underscores the company’s commitment to refining and enhancing the manufacturing workflows associated with advanced therapies.

GeminiBio operates as a supplier of essential raw materials for the biopharma and advanced therapy industries, providing vital solutions like serum, customized media, buffers, and process liquids. With Stober's extensive background in biopharmaceuticals, his appointment is a strategic choice aimed at addressing the complex challenges faced in biologics manufacturing.

Stober is not new to this space; he brings with him a wealth of experience accumulated over years at leading pharmaceutical companies, including Novartis, Merck, Pfizer, and GlaxoSmithKline. Currently, he serves as the CEO of Abzena, a Contract Development and Manufacturing Organization (CDMO) that specializes in biologics. His experience encompasses both the development and operational facets of cell and gene therapy, making him an invaluable addition to GeminiBio.

Cory Stevenson, Executive Chairman of the board, highlighted the importance of Stober's knowledge in enhancing customer-centric production processes. “Matt’s experience across different therapeutic manufacturing processes, combined with his insight into the critical nature of raw materials, positions us to significantly improve efficiency and production capabilities,” he stated.

Stober has articulated his eagerness to support GeminiBio in optimizing its role within the supply chain for biopharmaceutical manufacturers. In his view, suppliers like GeminiBio are foundational to the success of the biopharma industry, where successful partnerships are essential for achieving cost-effective and timely delivery of life-saving therapeutics.

As the biopharma landscape continues to evolve, the need for innovation in manufacturing practices becomes increasingly eminent. Stober’s focus will likely address how GeminiBio can better aid its clients by ensuring that raw materials and products are seamlessly integrated into the production workflows that ultimately lead to therapeutic development and commercialization.

In addition to his role at GeminiBio, Matt Stober serves on several other boards, including Leiters Health, Istari Oncology, and CastleVax, showcasing his active engagement in shaping the future of the healthcare landscape.

About GeminiBio

GeminiBio is a prominent player in the biopharma sector, specializing in providing services and materials to support the rapid advancement of therapeutic developments. Established in 1985 and based in West Sacramento, California, GeminiBio focuses on helping clients streamline the manufacturing processes essential for cell culture, leading to enhanced outcomes in biotherapeutics production. The company's manufacturing facilities encompass 57,000 square feet of cGMP-certified space, dedicated to both animal-origin-free and animal-component manufacturing—an essential consideration for regulatory compliance in the biotechnology sphere.

With a firm commitment to quality, GeminiBio holds certification under ISO 13485:2016 and is registered with the FDA as a Class 1 Medical Device Manufacturer, ensuring their products meet the rigorous standards necessary for the sensitive biotechnology environment.

As Matthew Stober takes on this pivotal role, the industry will be watching closely to see how his insights translate into innovations in biopharmaceutical manufacturing processes at GeminiBio. There is no doubt that his expertise will steer the company towards achieving greater efficiencies and deeper market penetration in the highly competitive biopharma landscape.